Recent research have converged on the overlap of GLP|GIP|GCGR stimulant therapies and dopamine communication. While GIP activators are widely employed for addressing type 2 T2DM, their emerging impacts on reinforcement circuits, specifically mediated by dopaminergic networks, are gaining substant